Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Genetic polymorphism of drug metabolizing enzymes and transporters may influence drug response. The frequency varies substantially between ethnicities thus having implications on appropriate selection and dosage of various drugs in different populations. The distribution of genetic polymorphisms in healthy Pakistanis has so far not been described. In this study, 155 healthy adults (98 females) were included from all districts of Karachi. DNA was extracted from saliva and genotyped for relevant SNVs in CYP 1 A1, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 as well as ALDH3A1, GSTA1, ABCB1 and ABCC2. About 64% of the participants were born to parents who were unrelated to each other. There was generally a higher prevalence (p < 0.05) of variant alleles of CYP450 1A2, 2B6, 2C19, 3A5, ALDH3A1, GSTM1 as well as ABCB1 and ABCC2 in this study cohort than in other ethnicities reported in the HapMap database. In contrast, the prevalence of variant alleles was lower in GSTA1. Therefore, in the Pakistani population sample from Karachi a significantly different prevalence of variant drug metabolizing enzymes and ABC transporters was observed as compared to other ethnicities, which could have putative clinical consequences on drug efficacy and safety.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

          Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pharmacogenomics in the clinic.

            After decades of discovery, inherited variations have been identified in approximately 20 genes that affect about 80 medications and are actionable in the clinic. And some somatically acquired genetic variants direct the choice of 'targeted' anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are moving away from discovery and towards implementation of an evidenced-based strategy for improving the use of medications, thereby providing a cornerstone for precision medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

              This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
                Bookmark

                Author and article information

                Contributors
                drnasirpk@yahoo.com
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                13 May 2019
                13 May 2019
                2019
                : 9
                : 7323
                Affiliations
                [1 ]Jinnah Medical and Dental College, Sohail University, 22-23 Shaheed-e-Millat Road, Karachi, 75400 Pakistan
                [2 ]ISNI 0000 0001 2153 9986, GRID grid.9764.c, Institute of Experimental and Clinical Pharmacology, , Christian Albrechts University Kiel, ; Hospitalstr. 4, Kiel, 24105 Germany
                [3 ]ISNI 0000 0001 2180 3484, GRID grid.13648.38, Department of Internal Medicine I, , University Medical Center Hamburg-Eppendorf, ; Hamburg, Germany
                [4 ]ISNI 0000 0001 0633 6224, GRID grid.7147.5, Department of Biological and Biomedical Sciences, , The Aga Khan University, ; Karachi, Pakistan
                [5 ]ISNI 0000 0004 0608 0996, GRID grid.419263.b, Sindh Institute of Urology and Transplantation, ; Karachi, Pakistan
                [6 ]ISNI 0000 0004 0637 9066, GRID grid.415915.d, Present Address: Liaquat National Hospital & Medical College, ; Karachi, Pakistan
                Author information
                http://orcid.org/0000-0002-2182-9534
                Article
                43736
                10.1038/s41598-019-43736-z
                6514210
                31086207
                598ae06b-f4c8-4fc0-8687-472f4d035007
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 29 August 2018
                : 10 April 2019
                Funding
                Funded by: Alfaisal University, Riyadh, Saudi Arabia (No.314140202132).
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                rare variants,translational research
                Uncategorized
                rare variants, translational research

                Comments

                Comment on this article